Andrew L. Pecora, MD | Authors

Articles

Exploring the Combination Anti-CTLA-4 and Anti-PD-1 in Multiple Myeloma Post-Transplant

May 25, 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the significance of his findings when combining an anti-CTLA-4 and anti-PD-1 in patients with multiple myeloma. He sought out to find whether these 2 drugs could be combined safely after an autologous stem cell transplant.

Results for Ipilimumab and Nivolumab Following Autologous Stem Cell Transplant in Multiple Myeloma

January 11, 2018

Andrew L. Pecora, MD, President of the Physician Services Division and Chief Innovation Officer at Hackensack Meridian Health, discusses preliminary safety and efficacy data for combined checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) as consolidation therapy following autologous stem cell transplant in patients with multiple myeloma and non-Hodkin lymphoma.